Rational approach to hormonal therapy among women after 40 years


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The necessity and possibility of using of hormonal drugs for women over 40 may could be associated with certain difficulties. On the one hand, they have the possibility of conceiving and unwanted pregnancy. On the other hand, after 40 years, the percentage of uterus pathology increases, as well as extragenital pathology which complicates the use of hormonal therapy. Another important question is the duration of the use of combined oral contraceptives (COCs) and for the transition to menopausal hormone therapy.

Full Text

Restricted Access

About the authors

Svetlana O. Dubrovina

Rostov State Medical University, Ministry of health of Russia

Email: s.dubrovina@gmail.com
MD, professor, the main scientific researcher of Scientific Research Institute of Obstetric and Pediatric

References

  1. Marret H., Fauconnier A., Chabbert-Buffet N., Cravello L., Golfier F., Gondry J. et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010; 152(2): 133-7.
  2. Munro M.G., et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J. Gynecol Obstet. 2011; 113(1): 3-13.
  3. Heavy menstrual bleeding: assessment and management. NICE guideline. Published: 14 March 2018 nice.org.uk/guidance/ng88
  4. Дубровина C-О. Комбинированные оральные контрацептивы: преимущества и риски. Акушерство и гинекология. 2017; 9: 132-7. http://dx.doi.org/10.18565/aig.2017.9.132-7.
  5. Madden Т., Secura G.M., Nease R.F., Politi М. С., Peipert J.F. The role of contraceptive attributes in women’s contraceptive decision making. Am J. Obstet Gynecol. 2015; 213: 46.e1-6. http://dx.doi.org/10.1016/j.ajog.2015.01.051
  6. Tricotel A., Collin C., Zureik M. Impact of the sharp changes in the use of contraception in 2013 on the risk of pulmonary embolism in France. Journal of Thrombosis and Haemostasis. 2013; 13: 1576-80.
  7. Madigan D., Shin J. Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database. Open Access Journal of Contraception 2018: 9: 29-32. https://doi.org/10.2147/OAJC.S161737
  8. de Bast os M., Stegeman B.H., Rosendaal F.R., Van Hylckama Vlieg A., Helmerhorst F.M., Stijnen Т., et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014; (3): CD010813.
  9. Информационное письмо Федеральной службы по надзору в сфере здравоохранения (Росздравнадзор) «О новых данных по безопасности комбинированных гормональных контрацептивных препаратов» от 20.03.2019 № 01и-778/19.
  10. Lidegaard О. Severely biased review of studies assessing the risk of venous thrombosis in users of drospirenone-containing oral contraceptives. An International Journal of Obstetrics and Gynecology. 2018: 125(8): 929-31. doi: 10.1111/1471-0528.15211
  11. Moon Kyoung Cho. Use of Combined Oral Contraceptives in Perimenopausal Women. Chonnam Med J. 2018; 54: 153-8. doi: 10.4068/cmj.2018.54.3.153
  12. Curtis K.M., Jatlaoui T.C., Tepper N.K., Zapata L.B., Horton L.G., Jamieson D.J., et al. U.S. Selected Practice Recommendations for contraceptive Use, 2016. MMWR Recomm Rep. 2016; 65: 1-66.
  13. Shifren J.L., Gass M.L. NAMS Recommendations for Clinical Care of Midlife Women Working Group. The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014; 21: 1038-62. doi: 10.1097/gme.0000000000000319
  14. American Society for Reproductive Medicine. The menopausal transition (perimenopause): what is it? Am Soc Reprod Med 2015. Available from: https://www.reproductivefacts.org/news-and-publications/patient-fact-sheets-and-booklets/documents/fact-sheets-and-info-booklets/the-menopausal-transition-perimenopause-what-is-it/
  15. Менопауза и климактерическое состояние у женщины. Клинические рекомендации РОАГ. КР117. 2016. 45 с.
  16. Lockwood C.J. Mechanisms of normal and abnormal endometrial bleeding. Menopause. 2011; 18(4): 408-11. doi: 10.1097/GME.0b013e31820bf288
  17. Rizner T.L., Brozic P., Doucette C., Turek-Etienne T., Muller-Vieira U., Sonneveld E., et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011; 76(6): 607-15. doi: 10.1016/j. steroids.2011.02.043.
  18. Podzolkova N., Tatarchuk T., Doshchanova A., Eshimbetova G., Pexman-Fieth C. Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study. Gynecol Endocrinol. 2016 Mar; 32(3): 246-9. doi: 10.3109/09513590.2015.1115832
  19. Trivedi N., Chauhan N., Vaidya V. Effectiveness and safety of dydrogesterone in regularization of menstrual cycle: a post-marketing study. Gynecol Endocrinol. 2016 Aug; 32(8): 667-71.
  20. Tajjamal A., Zaman F. Severity of bleeding is a predictor of quality of life in women with heavy menstrual bleeding under dydrogesterone treatment in a prospective, multicentre, observational study. Gazzetta Medica Italiana 2015; 174(9):391-398;
  21. Baber R.J., Panay N., Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 19 (2): 109-50. doi: 10.3109/13697137.2015.1129166
  22. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause: The Journal of The North American Menopause Society. 24 (7): 728-753. doi: 10.1097/GME.0000000000000921.
  23. Slopien R., Wender-Ozegowska E., Rogowicz-Frontczak A., Meczekalski B., Zozulinska-Ziolkiewicz D., Jaremek J.D. et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018; 117: 6-10. doi: 10.1016/j.maturitas.2018.08.009.
  24. Vinogradova Y., Coupland C., Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019; 364: k4810. https:// doi.org/10.1136/bmj.k4810
  25. Fritz M.A., Speroff L. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia (PA): Wolters Kluwer Health/Lippincott Williams & Wilkins, 2011: 1047.
  26. Linton A., Golobof A., Shulman L.P. Contraception for the perimenopausal woman. Climacteric. 2016; 19: 526-34.
  27. Baldwin M.K., Jensen J.T. Contraception during the perimenopause. Maturitas. 2013; 76: 235-42. doi: 10.1016/j.maturitas.2013.07.009
  28. Дубровина С.О., Берлим Ю.Д. Медикаментозное лечение боли, связанной с эндометриозом. Акушерство и гинекология. 2019; 2: 34-40. https://dx.doi.org/10.18565/aig.2019.2.34-40
  29. Giovanni G., Fabio B., Simone F., Filomena G. S., Emma B., Antonella N., Fabio F. Hormonal contraception in women with endometriosis: a systematic review. The European Journal of Contraception & Reproductive Health Care. doi: 10.1080/13625187.2018.1550576
  30. Quaas A.M., Weedin E.A., Hansen K.R. On-label and off-label drug use in the treatment of endometriosis. Fertil Steril. 2015; 103: 612-25. doi: 10.1016/j. fertnstert.2015.01.006
  31. Ferrero S. Endometriosis: modern management of an ancient disease. Eur J Obstet Gynecol Reprod Biol. 2017; 209: 1-2. doi: 10.1016/j.ejogrb.2016.12.036
  32. Grandi G., Facchinetti F., Bitzer J. Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle? Eur J Contracept Reprod Health Care. 2017; 22: 245-46. doi: 10.1080/13625187.2017.1372571

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies